Rozet F., Hennequin C., Beauval J. B., Beuzeboc P., Cormier L., Fromont G., Mongiat-Artus P., Ouzzane A., Ploussard G., Azria D., Brenot-Rossi I., Cancel-Tassin G., Cussenot O., Lebret T., Rebillard X., Soulié M., Renard-Penna R., Méjean A.   [CCAFU french national guidelines 2016-2018 on prostate cancer].  Prog. Urol..  2016 ;27 Suppl 1 :S95-S143

OBJECTIVES: The purpose of the guidelines national committee CCAFU was to propose updated french guidelines for localized and metastatic prostate cancer (PCa). METHODS: A Medline search was achieved between 2013 and 2016, as regards diagnosis, options of treatment and follow-up of PCa, to evaluate different references with levels of evidence. RESULTS: Epidemiology, classification, staging systems, diagnostic evaluation are reported. Disease management options are detailed. Recommandations are reported according to the different clinical situations. Active surveillance is a major option in low risk PCa. Radical prostatectomy remains a standard of care of localized PCa. The three-dimensional conformal radiotherapy is the technical standard. A dose of > 74Gy is recommended. Moderate hypofractionation provides short-term biochemical control comparable to conventional fractionation. In case of intermediate risk PCa, radiotherapy can be combined with short-term androgen deprivation therapy (ADT). In case of high risk disease, long-term ADT remains the standard of care. ADT is the backbone therapy of metastatic disease. In men with metastases at first presentation, upfront chemotherapy combined with ADT should be considered as a new standard. In case of metastatic castration-resistant PCa (mCRPC), new hormonal treatments and chemotherapy provide a better control of tumor progression and increase survival. CONCLUSIONS: These updated french guidelines will contribute to increase the level of urological care for the diagnosis and treatment for prostate cancer. (c) 2016 Elsevier Masson SAS. All rights reserved.

Carlsson S., de Carvalho T., Roobol M., Hugosson J., Auvinen A., Kwiatkowski M., Villers A., Zappa M., Nelen V., Paez A., Eastham J., Lilja H., de Koning H., Vickers A., Heijnsdijk E.   ESTIMATING THE HARMS AND BENEFITS OF PROSTATE CANCER SCREENING: COMPARING COMMON CLINICAL PRACTICE TO RECOMMENDED GOOD PRACTICE.  J. Urol..  2016 ;195 :E235-E235
Brahim W., Mestiri M., Betrouni N., Hamrouni K.   Semi-automated Rib Cage Segmentation in CT Images For Mesothelioma Detection.  -.  2016 ;-
Bougherara L., Blache G., Arsene E., Jauffret C., Azais H., Laplane C., Hudry D., Atrous G., Knight S., Bresson L., Kakkos A., Narducci F., Leblanc E., Houvenaeghel G., Bats A. S., Lecuru F., Collinet P., Marchal F., Lambaudie E.   Robotic Surgery in Gynecologic Oncology.  Oncologie.  2016 ;18 :287-297
Borget I., Dalle S., Leccia M., Dutriaux C., Stoebner P., Dalac S., Aubin F., Saiag P., Lacour J. P., Lesimple T., Dupuy A., Mortier L., Beylot-Barry M., Maubec E., Descamps V., Lok C., Stephan A., Guillot B., de Quatrebarbes J., Dreno B., Gally S., Mouri M., Allayous C., Kowal A., Porcher R., Lebbe C.   EFFECTIVENESS AND SAFETY OF VEMURAFENIB AS MONOTHERAPY IN UNRESECTABLE OR METASTATIC MELANOMA FROM AN ACADEMIC DATABASE: REAL WORLD DATA TO STRENGTHEN EVIDENCE FOR PAYER.  Value Health.  2016 ;19 :A762-A763
Blank C., Lorigan P., Schachter J., Robert C., Ribas A., Long G. V., Arance A., Mortier L., Daud A., Carlino M. S., McNeil C., Lotem M., Larkin J., Neyns B., Petrella T. M., Hamid O., Zhou H., Ebbinghaus S., Ibrahim N., Grob J. J.   Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.  Melanoma Res..  2016 ;26 :E117-E118
Beauval J. B. B., Ouzzane A., Ploussard G., Patard P. M., Gougeon A., Marcq G., Mathieu R., Vincendeau S., Hennequin C., Penna R. R., Cormier L., Azria D., Beuzeboc P., Artus P. M., Fromont G., De La Taille A., Roupret M., Soulie M., Salomon L., Mejean A., Rozet F.   A NEW SUBCLASSIFICATION SYSTEM FOR DECISION MAKING WITH INTERMEDIATE RISK PROSTATE CANCER PATIENTS TREATED BY RADICAL PROSTATECTOMY: A MULTICENTER STUDY.  J. Urol..  2016 ;195 :E558-E559
Bassil A., Azais H., Wacrenier A., Mordon S., Frochot C., Collinet P., Betrouni N.   TOLERANCE OF PATHOGEN FREE TISSUES FOR PDT WITH FOLATE ADRESSED PS IN OVARIAN PERITONEAL CARCINOSIS.  Lasers Surg. Med..  2016 ;48 :53-53
Basset-Seguin N., Hansson J., Kunstfeld R., Grob J. J., Dreno B., Mortier L., Ascierto P. A., Dimier N., Fittipaldo A., Xynos I., Hauschild A.   Subgroup analysis of patients (pts) with Gorlin syndrome treated with vismodegib (VISMO) in the STEVIE study.  Ann. Oncol..  2016 ;27
Basset-Seguin N., Dupuy A., Saiag P., Dalac-Rat S., Guillot B., Routier E., Leccia M. T., Duhamel A., Mirabel X., Benbouta I., Mirakovska L., Meddour D., Dib M., Mahmoudi A., Guerreschi P., Mortier L.   VISMONEO - a phase II study assessing vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma - Patients characteristics.  Ann. Oncol..  2016 ;27